# Senolytic Agent Improve the Benefit of Platelet-Rich Plasma and Losartan

> **NCT05025956** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Steadman Philippon Research Institute** · enrollment: 68 (estimated)

## Conditions studied

- Femoroacetabular Impingement

## Interventions

- **DRUG:** Fisetin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05025956
- **Lead sponsor:** Steadman Philippon Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-24
- **Primary completion:** 2024-10-31
- **Final completion:** 2024-10-31
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2024-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05025956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05025956, "Senolytic Agent Improve the Benefit of Platelet-Rich Plasma and Losartan". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05025956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*